about
Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexesBreast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) triEvaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women.Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trialConjugated estrogens for the treatment of menopausal symptoms: a review of safety data.Selective estrogen receptor modulators (SERMs): a review of clinical data.TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol.Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapyPrevalence of menopausal symptoms among mid-life women: findings from electronic medical records.Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.Factors associated with an optimal pregnancy outcome in an oocyte donation programImpact of transabdominal ultrasound guidance on performance and outcome of transcervical uterine embryo transfer.A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiolManagement of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combinationBehaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countriesPrescribing of FDA-approved and compounded hormone therapy differs by specialty.The tissue selective estrogen complex: a promising new menopausal therapyThe REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.Evolution of the tissue selective estrogen complex (TSEC).Tissue-selective estrogen complexes for postmenopausal women.Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.Differential effects of menopausal therapies on the endometrium.Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.An overview of current and emerging SERMs.Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
P50
Q30275835-5FCD08F4-80E8-4C0F-92FC-631F5C1F42F8Q30277010-C8AE7856-D91C-4B92-A3EB-2A1F4B571AC2Q30409045-C1FA4B02-209C-4F8B-8718-F4524DACA595Q30456359-10F65D24-3869-4E4C-B3C2-60550D8E613BQ30456640-6232BB3A-51F8-4166-8B3A-670383F3AE5DQ30456845-CD95EEC2-95D9-4770-B66E-2302CC68ACE3Q30456878-4680C054-6A35-4DF5-B60C-10E199334CDFQ30457122-625137BC-550C-46EB-BD14-997C7F4E18DDQ30457279-F97A0760-1E99-48B6-A29D-945695127F3EQ30457307-398F581D-9E13-45E2-BCEA-30FFA5EA32C5Q30457317-4D5D19B5-2522-4ED8-A83F-EAC911497F27Q30458166-8F4DED83-A20A-4441-9801-EAF7A34DFA51Q30490900-14AC2F04-A0C1-40C5-AC76-560DEDD07477Q30491432-43E65046-DF97-4917-820F-B5684D8D8FF2Q30659580-2D943803-605B-4046-A458-82209A7858E9Q30873899-85AEF952-6495-4BE8-9CDC-B3A910682078Q33601408-1203A86C-10FB-42A4-8F65-E83ED509E004Q33745882-ABC93475-B206-43CB-A326-E147F5B4ADE7Q33907889-86103320-C66F-411D-88AE-4E5E944EB75CQ34475143-C176673C-41FC-4CC6-9806-3C7AE749EDD3Q35745280-2C1F516E-900D-4A04-AC1A-02EE5FFC050BQ35885187-E52E3BF2-63EB-44FE-B95F-A6C61FD66D5AQ36269324-2B24800B-5A51-4DC3-9EA5-07B8A0F4E3DFQ36269781-4DF6F4D2-5C9A-45DF-B8C9-745C6514461EQ36330821-58F66ED5-DC7E-4798-81FE-BB99D3FAA328Q36846471-438CA844-F57A-4C22-B997-47E1815302C0Q37095740-33D43D36-4C5D-481C-B040-D5468492AE99Q37248714-1C0D72BC-0031-46FB-BD8E-ED435B963012Q37265844-6B791D13-DCB2-4EEE-A46B-7FBA94389E24Q37277298-B5C0E65B-12A2-45F3-8AF4-35887F36CE22Q37722587-B2AE5292-A33E-4C19-9512-FFE6CBC18F77Q37966131-4FEA6817-B837-4530-B0B9-134EF3DC9B73Q38077503-A8A3FC50-60CD-4C42-BB05-499934CA653FQ38121256-648234D3-2D6E-4ADB-BA45-9E4CCF60D95BQ38163623-72583F1D-CD48-4752-BFFB-5C01C4331C88Q38187230-3B91E089-9278-4FF4-A4D8-D773ACFD36E7Q38193873-DB82CEAD-6B6F-4175-BE2C-991DC7A008E7Q38199300-ACD9C270-C670-4255-B6F7-1B8B783834B5Q38207724-0BF5C0A1-0F6D-41E4-8DDA-76197B6E5B5EQ38220193-5F04F119-05DD-40FE-A524-6ECA2EDC0186
P50
name
Sebastian Mirkin
@ast
Sebastian Mirkin
@en
Sebastian Mirkin
@nl
type
label
Sebastian Mirkin
@ast
Sebastian Mirkin
@en
Sebastian Mirkin
@nl
prefLabel
Sebastian Mirkin
@ast
Sebastian Mirkin
@en
Sebastian Mirkin
@nl